Clinical trials: Bowel Disease
Colorectal Neoplasms
A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
The study is designed to demonstrate that the combination of AG-013736 with either FOLFIRI or FOLFOX is superior to FOLFIRI or FOLFOX in combination with bevacizumab (Avastin) in delaying tumor progression in the second-line…
- Trial name
- NCT00615056
- Testing
- Bevacizumab (avastin), FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU]), AG-013736 (axitinib)
- Where
- 83 sites in United States, Canada and 6 more
- Volunteers
- 171 people
- Sponsor
- Pfizer
Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
This phase I/II trial studies the side effects and the best dose of veliparib when given together with bendamustine hydrochloride and rituximab and to see how well they work in treating patients with lymphoma, multiple myeloma…
- Conditions
- Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult Solid Neoplasm, Anaplastic Large Cell Lymphoma
- Trial name
- NCT01326702
- Testing
- Bendamustine Hydrochloride, Pharmacological Study, Rituximab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Ulcerative Colitis
Evaluation of SPH3127 in Patients With Mild-to-Moderate Ulcerative Colitis
SPH3127-US-01 is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics, and preliminary efficacy of SPH3127 for the treatment of mild-to-moderate ulcerative colitis.
- Trial name
- NCT05019742
- Testing
- SPH3127
- Where
- 16 sites in United States
- Volunteers
- 3 people
- Sponsor
- Shanghai Pharma Biotherapeutics USA Inc.
Metastatic Colorectal Cancer
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to assess the anti-tumor activity of MEK162 in combination with panitumumab.
- Trial name
- NCT01927341
- Testing
- MEK162, Panitumumab
- Where
- 8 sites in United States, Belgium and 5 more
- Volunteers
- 53 people
- Sponsor
- Pfizer
Functional Bowel Disorder
Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders
The parallel three-group study of efficacy and safety was planned to investigate the reduction in abdominal pain and bloating during treatment with the fixed-dose combination of Mebeverine + Simethicone versus Duspatalin® and…
- Trial name
- NCT05175131
- Testing
- Mebeverine+Simethicone, Mebeverine, Simethicone
- Where
- Russia
- Volunteers
- 465 people
- Sponsor
- Abbott
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer
A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies
To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer
- Trial name
- MDX1106-01 (NCT00441337)
- Testing
- MDX-1106
- Where
- 4 sites in United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Anal Canal Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8
Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial
This phase II trial studies the side effects of LET-IMPT and standard chemotherapy, and how well they work in treating patients with newly diagnosed stage I-III anal canal squamous cell cancer.
- Conditions
- Anal Canal Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage II Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
- Trial name
- NCT03690921
- Testing
- Cisplatin, Fluorouracil, Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
Crohn's Disease
Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)
Prospective, observational, parallel-group, postmarketing safety surveillance registry in participants treated with Remicade or standard therapy for active or fistulizing Crohn's disease (CD).
- Trial name
- ENCORE (NCT00705614)
- Testing
- Remicade
- Volunteers
- 2,662 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn Disease
A Dose-finding Study of OPC-6535 in Patients With Active Crohn's Disease
The purpose of this study to examine the safety and efficacy of OPC-6535 and determine its optimal dose by once-daily oral administration at 0, 25, or 50 mg for 8 weeks in combination with a fixed oral dose of 5-aminosalicylic…
- Trial name
- NCT00317369
- Testing
- OPC-6535(Tetomilast)
- Where
- 8 sites in Japan
- Volunteers
- 29 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Inflammatory Bowel Disease, Ulcerative Colitis
Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease
The investigators hypothesize that E-health - web based monitoring of disease and treatment - in young patients with chronic inflammatory disease (IBD) can improve the disease course and quality of life.
- Conditions
- Inflammatory Bowel Disease, Ulcerative Colitis, Crohn´s Disease
- Trial name
- NCT01860651
- Testing
- Web-monitoring
- Where
- Denmark
- Volunteers
- 103 people
- Sponsor
- Hvidovre University Hospital
Irritable Bowel Syndrome
SH-DS01 on Fecal Metagenomic Stability
This is a randomized, double blind, Phase 1 study. There will be a 12-week comparison of the safety of DS-01 versus placebo with a secondary outcome measure of the efficacy in a cohort of 100 men or women with IBS with…
- Trial name
- NCT04598295
- Testing
- DS-01
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Beth Israel Deaconess Medical Center
Colon Cancer
Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases
Preliminary studies with a variety of vaccines suggest target accessibility (potential immunogenicity) in a variety of solid tumors to immune directed approaches.
- Trial name
- FANG-CLM (NCT01505166)
- Testing
- Vigil™ Vaccine
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gradalis, Inc.
Ulcerative Colitis
Dose Escalation and Remission (DEAR)
The proposed study will test whether increasing Lialda dose can reduce fecal calprotectin (FCP) levels, a marker of intestinal inflammation that is highly predictive of the risk of relapse among patients with quiescent ulcerative…
- Trial name
- DEAR (NCT00652145)
- Testing
- mesalamine
- Where
- 8 sites in United States
- Volunteers
- 119 people
- Sponsor
- James Lewis
Colorectal Cancer
A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer
The purpose of the study is to describe the tumor response rates for the two regimens being studied, and to determine how long patients live after receiving the treatment, how long patients are without return of their disease…
- Trial name
- NCT00192075
- Testing
- Gemcitabine, avastin, 5FU/folinic acid
- Where
- 15 sites in United States
- Volunteers
- 84 people
- Sponsor
- Eli Lilly and Company
Colorectal Neoplasms
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
This trial will evaluate the safety and efficacy of vicriviroc (MK-7690) at 2 dose levels in combination with pembrolizumab (MK-3475) in participants with advanced/metastatic microsatellite stable (MSS) colorectal cancer (CRC).
- Trial name
- NCT03631407
- Testing
- Vicriviroc, Pembrolizumab
- Where
- 8 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Cancer
Community Collaboration to Advance Racial/Ethnic Equity in CRC Screening
The goal of this pragmatic randomized clinical trial is to compare two colorectal (CRC) screening outreach approaches (FIT and Cologuard) in community health centers (CHC) in patients overdue for CRC screening.
- Trial name
- CARES (NCT05714644)
- Testing
- FIT kit Screening Test, Cologuard Screening Test
- Where
- 3 sites in United States
- Volunteers
- 5,127 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Eosinophilic Gastritis or Gastroenteritis
Benralizumab for Eosinophilic Gastritis (BEGS)
A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Benralizumab (Anti-IL5RA) in Subjects With Eosinophilic Gastritis.
- Trial name
- BEGS (NCT03473977)
- Testing
- Benralizumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Ulcerative Colitis
A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis
The purpose of the study is to evaluate the effectiveness and safety of infliximab (Remicade) in children with moderately to severely active ulcerative colitis.
- Trial name
- NCT00336492
- Testing
- infliximab
- Where
- 27 sites in United States, Belgium and 3 more
- Volunteers
- 60 people
- Sponsor
- Centocor, Inc.
Inflammatory Bowel Diseases, Ulcerative Colitis
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease
This is a post-marketing observational study of patients with Inflammatory Bowel Disease (specifically, Crohn's disease or Ulcerative Colitis) who have been prescribed CT-P13 (infliximab) or Remicade (infliximab) for treatment.
- Conditions
- Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn's Disease
- Trial name
- CONNECT-IBD (NCT02539368)
- Testing
- CT-P13, Remicade
- Where
- 140 sites in Belgium, Czechia and 11 more
- Volunteers
- 2,565 people
- Sponsor
- Pfizer
Prematurity, Anemia
Transfusions and Nitric Oxide Level in Preterm Infants
The purpose of this study is to better understand S-nitrosohemeglobin (SNO-Hb) in transfused blood of extremely preterm infants.
- Conditions
- Prematurity, Anemia, Necrotizing Enterocolitis
- Trial name
- NCT00787124
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Duke University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.